Nordic Life Science 1
PH A SE I I THE COMPANY HAS ANNOUNCED THE COMPLET
E ANALYSIS OF THE DATA FROM THE PHASE II MERECA CLINICAL TRIAL. THE STUDY EVALUATED the therapeutic impact of the company’s lead candidate, ilixadencel, in combination with Sutent (sunitinib) in metastatic Renal Cell Carcinoma (RCC) patients. The data on survival benefit in all patients showed that a higher percentage of ilixadencel patients were alive as per data cut-off in July 2019. Among the responders, meaning the patients with Complete Responses (CR) and Partial Responses (PR), the addition of ilixadencel to sunitinib induced stronger and more durable tumor responses. These results indicate that ilixadencel provides a systemic therapeutic benefit while maintaining a positive safety and tolerability profile. Overall the data supports the continued clinical development of ilixadencel as an immune primer in RCC and other solid tumors.